PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Evolocumab

Chanukya Dahagam; Aditya Goud; Abdelhai Abdelqader; Aditya Hendrani; Matthew J. Feinstein; Arman Qamar; Parag H. Joshi; Kristopher J. Swiger; Kathleen Byrne; Renato Quispe; Steven R. Jones; Roger S. Blumenthal; Seth S. Martin

doi:10.2217/fca.15.89

PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Evolocumab

Chanukya Dahagam, Aditya Goud, Abdelhai Abdelqader, Aditya Hendrani, Matthew J. Feinstein, Arman Qamar, Parag H. Joshi, Kristopher J. Swiger, Kathleen Byrne, Renato Quispe, Steven R. Jones, Roger S. Blumenthal, Seth S. Martin

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Patients with familial hypercholesterolemia or statin intolerance are especially challenging to manage since LDL cholesterol levels often remain considerably elevated despite clinicians' best efforts. With statins regarded as first-line pharmacologic therapy by the current American College of Cardiology/American Heart Association guidelines to reduce LDL cholesterol and cardiovascular risk, there is now a critical need to determine when other agents will play a role beyond maximally tolerated statin therapy and lifestyle changes. In this review, we take a closer look at evolocumab (Repatha®), one of the new injectable human monoclonal antibodies to PCSK9 and its efficacy and safety properties from the results of various trials.

Original language	English (US)
Pages (from-to)	139-148
Number of pages	10
Journal	Future Cardiology
Volume	12
Issue number	2
DOIs	https://doi.org/10.2217/fca.15.89
State	Published - Mar 2016

Keywords

LDL
PCSK9 inhibitors
alirocumab
evolocumab
monoclonal antibodies
statin intolerance

ASJC Scopus subject areas

Molecular Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.2217/fca.15.89

Cite this

@article{8d722a63686b4b9db2b8f9b05bedb5a0,

title = "PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Evolocumab",

abstract = "Patients with familial hypercholesterolemia or statin intolerance are especially challenging to manage since LDL cholesterol levels often remain considerably elevated despite clinicians' best efforts. With statins regarded as first-line pharmacologic therapy by the current American College of Cardiology/American Heart Association guidelines to reduce LDL cholesterol and cardiovascular risk, there is now a critical need to determine when other agents will play a role beyond maximally tolerated statin therapy and lifestyle changes. In this review, we take a closer look at evolocumab (Repatha{\textregistered}), one of the new injectable human monoclonal antibodies to PCSK9 and its efficacy and safety properties from the results of various trials.",

keywords = "LDL, PCSK9 inhibitors, alirocumab, evolocumab, monoclonal antibodies, statin intolerance",

author = "Chanukya Dahagam and Aditya Goud and Abdelhai Abdelqader and Aditya Hendrani and Feinstein, {Matthew J.} and Arman Qamar and Joshi, {Parag H.} and Swiger, {Kristopher J.} and Kathleen Byrne and Renato Quispe and Jones, {Steven R.} and Blumenthal, {Roger S.} and Martin, {Seth S.}",

note = "Publisher Copyright: {\textcopyright} 2016 Future Medicine Ltd.",

year = "2016",

month = mar,

doi = "10.2217/fca.15.89",

language = "English (US)",

volume = "12",

pages = "139--148",

journal = "Future Cardiology",

issn = "1479-6678",

publisher = "Future Medicine Ltd.",

number = "2",

}

TY - JOUR

T1 - PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels

T2 - Evolocumab

AU - Dahagam, Chanukya

AU - Goud, Aditya

AU - Abdelqader, Abdelhai

AU - Hendrani, Aditya

AU - Feinstein, Matthew J.

AU - Qamar, Arman

AU - Joshi, Parag H.

AU - Swiger, Kristopher J.

AU - Byrne, Kathleen

AU - Quispe, Renato

AU - Jones, Steven R.

AU - Blumenthal, Roger S.

AU - Martin, Seth S.

PY - 2016/3

Y1 - 2016/3

N2 - Patients with familial hypercholesterolemia or statin intolerance are especially challenging to manage since LDL cholesterol levels often remain considerably elevated despite clinicians' best efforts. With statins regarded as first-line pharmacologic therapy by the current American College of Cardiology/American Heart Association guidelines to reduce LDL cholesterol and cardiovascular risk, there is now a critical need to determine when other agents will play a role beyond maximally tolerated statin therapy and lifestyle changes. In this review, we take a closer look at evolocumab (Repatha®), one of the new injectable human monoclonal antibodies to PCSK9 and its efficacy and safety properties from the results of various trials.

AB - Patients with familial hypercholesterolemia or statin intolerance are especially challenging to manage since LDL cholesterol levels often remain considerably elevated despite clinicians' best efforts. With statins regarded as first-line pharmacologic therapy by the current American College of Cardiology/American Heart Association guidelines to reduce LDL cholesterol and cardiovascular risk, there is now a critical need to determine when other agents will play a role beyond maximally tolerated statin therapy and lifestyle changes. In this review, we take a closer look at evolocumab (Repatha®), one of the new injectable human monoclonal antibodies to PCSK9 and its efficacy and safety properties from the results of various trials.

KW - LDL

KW - PCSK9 inhibitors

KW - alirocumab

KW - evolocumab

KW - monoclonal antibodies

KW - statin intolerance

UR - http://www.scopus.com/inward/record.url?scp=84959908518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959908518&partnerID=8YFLogxK

U2 - 10.2217/fca.15.89

DO - 10.2217/fca.15.89

M3 - Review article

C2 - 26911710

AN - SCOPUS:84959908518

SN - 1479-6678

VL - 12

SP - 139

EP - 148

JO - Future Cardiology

JF - Future Cardiology

IS - 2

ER -

PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Evolocumab

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this